About
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS is a biopharmaceutical company founded as a joint venture by Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, to create the next generation of products along with actionable diagnostics to fight AntiMicrobial Resistance (AMR).
AUROBAC plans to work to shift the strategy related to antibiotic treatment regimens, which now leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.
AUROBAC will cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization.
AUROBAC is currently seeking to strengthen its product portfolio and is particularly interested in in-licensing or co-developing products developed to fight bacterial infections & AMR, with a focus on:
- New and alternative modalities like e.g., phage lysins, therapeutic antibodies, etc.;
- Novel target classes and mode of actions;
- Host Immune-modulation approaches;
- Products addressing high unmet medical needs;
- Targeted modalities that can be combined with rapid and actionable diagnostics and that are supported by new economic models.
“The rise of AntiMicrobial resistance worldwide jeopardizes the prevention and treatment of life-threatening resistant bacterial infections, which are already killing 1.3 million people per year. AUROBAC has the remarkable ambition to become a leader in AMR innovation with a unique combination of the best capabilities of the three founding companies, Boehringer Ingelheim, Evotec and bioMérieux.
Our strategy is to develop and commercialize safe and effective drugs using selected diagnostic approaches, in order to cure efficiently infected patients with minimized risks of recurrence and limited impact on disseminating resistance.“
Florence Séjourné, CEO.